Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

procept biorobotics corp - PRCT

PRCT

Close Chg Chg %
34.48 -1.65 -4.79%

Closed Market

32.83

-1.65 (4.79%)

Volume: 947.06K

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Trade Now

Company Overview: procept biorobotics corp - PRCT

PRCT Key Data

Open

$34.56

 Day Range

31.86 - 35.12

52 Week Range

27.80 - 87.45

 Market Cap

$1.90B

Shares Outstanding

55.88M

 Public Float

53.81M

Beta

0.99

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.54

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.05M

  

PRCT Performance

1 Week
 
 9.60%
 
1 Month
 
 -4.20%
 
3 Months
 
 4.74%
 
1 Year
 
 -60.30%
 
5 Years
 
 N/A
 

PRCT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About procept biorobotics corp - PRCT

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.

PRCT At a Glance

PROCEPT BioRobotics Corp.
150 Baytech Drive
San Jose, California 95134
Phone 1-650-232-7200 Revenue 224.50M
Industry Medical Specialties Net Income -91,413,000.00
Sector Health Technology 2024 Sales Growth 64.841%
Fiscal Year-end 12 / 2025 Employees 756
View SEC Filings

PRCT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 18.696
Price to Book Ratio 10.954
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -43.156
Enterprise Value to Sales 17.566
Total Debt to Enterprise Value 0.02

PRCT Efficiency

Revenue/Employee 296,955.026
Income Per Employee -120,916.667
Receivables Turnover 2.689
Total Asset Turnover 0.478

PRCT Liquidity

Current Ratio 9.069
Quick Ratio 8.011
Cash Ratio 6.281

PRCT Profitability

Gross Margin 61.069
Operating Margin -43.036
Pretax Margin -40.719
Net Margin -40.719
Return on Assets -19.476
Return on Equity -26.769
Return on Total Capital -18.947
Return on Invested Capital -21.795

PRCT Capital Structure

Total Debt to Total Equity 19.952
Total Debt to Total Capital 16.633
Total Debt to Total Assets 15.028
Long-Term Debt to Equity 19.477
Long-Term Debt to Total Capital 16.237
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Procept Biorobotics Corp - PRCT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
34.47M 75.01M 136.19M 224.50M
Sales Growth
+346.72% +117.60% +81.55% +64.84%
Cost of Goods Sold (COGS) incl D&A
18.61M 37.93M 65.14M 87.40M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.98M 4.32M 3.81M 5.23M
Depreciation
2.68M 4.02M 3.51M 4.93M
Amortization of Intangibles
300.00K 300.00K 300.00K 300.00K
COGS Growth
+107.40% +103.83% +71.75% +34.17%
Gross Income
15.87M 37.09M 71.05M 137.10M
Gross Income Growth
+1,364.14% +133.75% +91.58% +92.96%
Gross Profit Margin
+46.02% +49.44% +52.17% +61.07%
2021 2022 2023 2024 5-year trend
SG&A Expense
70.03M 117.81M 180.22M 233.71M
Research & Development
18.99M 28.98M 48.45M 62.30M
Other SG&A
51.04M 88.83M 131.77M 171.41M
SGA Growth
+50.45% +68.23% +52.98% +29.68%
Other Operating Expense
- - - -
-
Unusual Expense
(199.00K) 3.54M 107.00K 114.00K
EBIT after Unusual Expense
(53.97M) (84.27M) (109.28M) (96.73M)
Non Operating Income/Expense
(78.00K) 2.29M 7.38M 9.50M
Non-Operating Interest Income
76.00K 2.50M 7.55M 10.89M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
5.81M 5.18M 4.00M 4.18M
Interest Expense Growth
+10.44% -10.79% -22.92% +4.73%
Gross Interest Expense
5.81M 5.18M 4.00M 4.18M
Interest Capitalized
- - - -
-
Pretax Income
(59.85M) (87.15M) (105.90M) (91.41M)
Pretax Income Growth
-12.89% -45.61% -21.51% +13.68%
Pretax Margin
-173.62% -116.18% -77.76% -40.72%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(59.85M) (87.15M) (105.90M) (91.41M)
Minority Interest Expense
- - - -
-
Net Income
(59.85M) (87.15M) (105.90M) (91.41M)
Net Income Growth
-12.89% -45.61% -21.51% +13.68%
Net Margin Growth
-173.62% -116.18% -77.76% -40.72%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(59.85M) (87.15M) (105.90M) (91.41M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(59.85M) (87.15M) (105.90M) (91.41M)
EPS (Basic)
-1.3704 -1.9629 -2.241 -1.7537
EPS (Basic) Growth
-11.80% -43.24% -14.17% +21.74%
Basic Shares Outstanding
43.68M 44.40M 47.26M 52.13M
EPS (Diluted)
-1.3704 -1.9629 -2.241 -1.7537
EPS (Diluted) Growth
-11.80% -43.24% -14.17% +21.74%
Diluted Shares Outstanding
43.68M 44.40M 47.26M 52.13M
EBITDA
(51.19M) (76.41M) (105.36M) (91.38M)
EBITDA Growth
-13.49% -49.27% -37.90% +13.27%
EBITDA Margin
-148.48% -101.85% -77.36% -40.70%

Snapshot

Average Recommendation BUY Average Target Price 52.75
Number of Ratings 14 Current Quarters Estimate -0.324
FY Report Date 03 / 2026 Current Year's Estimate -1.141
Last Quarter’s Earnings -0.33 Median PE on CY Estimate N/A
Year Ago Earnings -1.511 Next Fiscal Year Estimate -0.615
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 14 12
Mean Estimate -0.32 -0.28 -1.14 -0.62
High Estimates -0.11 -0.11 -0.52 0.34
Low Estimate -0.45 -0.36 -1.53 -1.05
Coefficient of Variance -27.69 -22.75 -20.67 -62.27

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 11 11
OVERWEIGHT 0 0 0
HOLD 3 3 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Procept Biorobotics Corp - PRCT

Date Name Shares Transaction Value
Mar 21, 2025 Reza Zadno President, CEO; Director 173,070 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.06 per share 9,875,374.20
Mar 21, 2025 Kevin Waters EVP, CFO 107,991 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.06 per share 6,161,966.46
Mar 21, 2025 Alaleh Nouri EVP, CLO, CORP. SEC. 61,473 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.06 per share 3,507,649.38
Mar 21, 2025 Hisham Shiblaq EVP, Chief Comm. Officer 63,133 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.06 per share 3,602,368.98
Mar 6, 2025 Reza Zadno President, CEO; Director 36,831 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Kevin Waters EVP, CFO 14,388 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Alaleh Nouri EVP, CLO, CORP. SEC. 11,445 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Hisham Shiblaq EVP, Chief Comm. Officer 9,810 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 13, 2025 Frederic H. Moll Director 836,358 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.33 per share 1,112,356.14
Feb 13, 2025 Frederic H. Moll Director 841,621 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $0.86 per share 723,794.06
Feb 13, 2025 Frederic H. Moll Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 13, 2025 Frederic H. Moll Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Procept Biorobotics Corp in the News